随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
责任编辑：papersystem
，详情可参考51吃瓜
At the same time, Ultrahuman is pulling the covers off Jade, its new “real time biointelligence AI.” The company promises Jade will be able to “pull real-time actionable insights, and even start breathwork or trigger Afib detection.” Jade is expected to get new features over time, with some examples being ordering good, changing your room temperature or flagging potential health issues. The idea is that Jade will keep a constant eye on your health, pulling in data from the ring, M1 continuous glucose monitor and environmental stats from your Ultrahuman Home.
The plagiarism checker is a great way to ensure that your content is original.
// 易错点1：必须倒序遍历（正序无法正确缓存右侧的更大值）